Masaru Matsuda insider trades: Arcutis Biotherapeutics (ARQT) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Masaru reports to the SEC
Open-market buys and sales
26 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | ARQT | ↓ Sell | 41,219 | $34.24 | $1.4M | Direct | Nov 4, 2026 (0d) |
| Sep 16, 2026 | ARQT | ↓ Sell | 3,674 | $25.00 | $92K | Direct | Sep 18, 2026 (2d) |
| Aug 3, 2026 | ARQT | ↓ Sell | 1,230 | $26.12 | $32K | Direct | Aug 5, 2026 (2d) |
| May 4, 2026 | ARQT | ↓ Sell | 8,256 | $23.31 | $192K | Direct | May 6, 2026 (2d) |
| Feb 2, 2026 | ARQT | ↓ Sell | 40,638 | $25.28 | $1.0M | Direct | Feb 4, 2026 (2d) |
| Dec 1, 2025 | ARQT | ↓ Sell | 1,657 | $30.23 | $50K | Direct | Dec 3, 2025 (2d) |
| Nov 19, 2025 | ARQT | ↓ Sell | 2,550 | $28.29 | $72K | Direct | Nov 21, 2025 (2d) |
| Nov 3, 2025 | ARQT | ↓ Sell | 7,208 | $24.72 | $178K | Direct | Nov 5, 2025 (2d) |
| Sep 4, 2025 | ARQT | ↓ Sell10b5-1 | 36,130 | $16.16 | $584K | Direct | Sep 8, 2025 (4d) |
| Aug 4, 2025 | ARQT | ↓ Sell | 6,330 | $14.33 | $91K | Direct | Aug 5, 2025 (1d) |
| May 28, 2025 | ARQT | ↓ Sell | 1,800 | $13.78 | $25K | Direct | May 29, 2025 (1d) |
| May 2, 2025 | ARQT | ↓ Sell | 5,030 | $15.20 | $76K | Direct | May 5, 2025 (3d) |
| Mar 3, 2025 | ARQT | ↓ Sell | 3,263 | $13.03 | $43K | Direct | Mar 4, 2025 (1d) |
| Feb 3, 2025 | ARQT | ↓ Sell | 8,338 | $12.70 | $106K | Direct | Feb 4, 2025 (1d) |
| Nov 30, 2024 | ARQT | ↑ Buy | 5,657 | $3.28 | $19K | Direct | Dec 3, 2024 (3d) |
| Nov 19, 2024 | ARQT | ↓ Sell | 1,775 | $9.68 | $17K | Direct | Nov 19, 2024 (0d) |
| Nov 4, 2024 | ARQT | ↓ Sell | 5,015 | $8.68 | $44K | Direct | Nov 5, 2024 (1d) |
| Aug 2, 2024 | ARQT | ↓ Sell10b5-1 | 5,220 | $9.02 | $47K | Direct | Aug 5, 2024 (3d) |
| May 28, 2024 | ARQT | ↓ Sell | 1,775 | $9.01 | $16K | Direct | May 29, 2024 (1d) |
| May 2, 2024 | ARQT | ↓ Sell10b5-1 | 5,016 | $8.74 | $44K | Direct | May 3, 2024 (1d) |
| Mar 4, 2024 | ARQT | ↓ Sell | 3,760 | $11.12 | $42K | Direct | Mar 6, 2024 (2d) |
| Nov 21, 2023 | ARQT | ↓ Sell | 1,850 | $1.98 | $4K | Direct | Nov 21, 2023 (0d) |
| May 31, 2023 | ARQT | ↓ Sell | 1,830 | $7.80 | $14K | Direct | Jun 2, 2023 (2d) |
| Mar 2, 2023 | ARQT | ↓ Sell | 1,434 | $15.83 | $23K | Direct | Mar 6, 2023 (4d) |
| Nov 21, 2022 | ARQT | ↓ Sell | 1,720 | $18.19 | $31K | Direct | Nov 22, 2022 (1d) |
| Jun 2, 2022 | ARQT | ↓ Sell | 1,795 | $19.73 | $35K | Direct | Jun 2, 2022 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Masaru Matsuda's insider trades
Masaru Matsuda is EVP, Chief Legal Officer at Arcutis Biotherapeutics (ARQT). Since Jun 2, 2022, Masaru has reported 1 open-market purchase worth $19K and 25 sales worth $4.3M on SEC Form 4. In the last 12 months: 7 sales ($2.9M).
3 sales (16% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (14 filings), option exercises (5 filings), shares withheld for taxes (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.